Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 72K | 72K | 72K | 72K | 71K |
| Gross Profit | -814K | 66K | 66K | 66K | 66K |
| Operating Income | -4M | -5M | -4M | -4M | -3M |
| EBITDA | -4M | -4M | -4M | -4M | 4M |
| Net Income | -4M | -4M | -4M | -4M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$6.12
+5.34% today
1Y Change
-30.02%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Silo Pharma, Inc. (SILO) is a Healthcare stock with listed on NASDAQ. The stock last traded around $6.12 and down 30.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +58.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +58.0%, free cash flow -21.6% with operating margin -5937.0% and ROIC -61.5%. Valuation already assumes a fairly strong business story at price/sales 50.3. Stock Foundry combines SILO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SILO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SILO Max Drawdown
-65.52%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SILO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$71.3K
-1.2% YoY
FY Net Income
$3.9M
+199.9% YoY
Free Cash Flow
-$2.3M
+34.9% YoY
Revenue Growth
+0.0%
EPS Growth
+58.0%
Gross Margin
-602.8%
Net Margin
-5863.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 72K | 72K | 72K | 72K | 71K |
| Gross Profit | -814K | 66K | 66K | 66K | 66K |
| Operating Income | -4M | -5M | -4M | -4M | -3M |
| EBITDA | -4M | -4M | -4M | -4M | 4M |
| Net Income | -4M | -4M | -4M | -4M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 4M | 4M | 11M | 10M |
| Total Assets | 8M | 7M | 8M | 12M | 10M |
| Total Liabilities | 1M | 2M | 2M | 1M | 1M |
| Shareholder Equity | 6M | 5M | 6M | 10M | 9M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -5M | -4M | -4M | -11M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+34.9% YoY
Capital Expenditures
4
Free Cash Flow
2M
+34.9% YoY
Key ratios
Gross Margin
-602.8%
Operating Margin
-5937.0%
Net Margin
-5863.5%
ROE
-83.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.